Skip to content

Depression: all studies

Page 107 of 1,034: studies 1,061 to 1,070 of 10,336, newest first. Back to the depression overview

Research

Intravenous ketamine versus electroconvulsive therapy for major depressive disorder or bipolar depression: A meta-analysis of randomized controlled trials.

Journal of Affective Disorders February 15, 2025 Zhan-Ming Shi, Xian-Jun Lan, Qing Chen et al. 6 citations

Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar depression (BD), though the comparative outcomes remain inconclusive. This meta-analysis aimed to provide a systematic assessment of the efficacy, safety, and tolerability of IV ketamine relative to ECT for treating MDD or BD. Randomized controlled...

Penggunaan Mindfulness-Based Cognitive Therapy (MBCT) untuk Menurunkan Gejala Depresi Wanita dengan (Major Depressive Disorder (MDD)

JIIP - Jurnal Ilmiah Ilmu Pendidikan February 13, 2025 Hasrat Listaria Mailana, Ika Yuniar Cahyanti

Gangguan Depresi Mayor (Major Depressive Disorder/MDD) secara klinis ditandai dengan kehilangan minat dan kesulitan untuk merasa kepuasan dan kebahagiaan dalam kesehariannya. Kondisi ini harus berlangsung setidaknya 2 minggu atau lebih dan memengaruhi keberfungsian individu dalam keseharian. Individu yang mengalami gangguan ini biasanya terjebak dalam pemikiran yang negatif dan melakukan...

Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.

ACS Medicinal Chemistry Letters February 13, 2025 Ram W. Sabnis, Anika R. Sabnis

High Resolution Image Download MS PowerPoint Slide Provided herein are novel tryptamine compounds as 5-HT2A agonists, pharmaceutical compositions, use of such compounds in treating mood disorders such as depressive disorders and bipolar disorders and processes for preparing such compounds.

Effect of technology-supported mindfulness-based interventions for maternal depression: a systematic review and meta-analysis with implementation perspectives for resource-limited settings.

BMC Pregnancy and Childbirth February 13, 2025 Bekelu Teka Worku, Misra Abdulahi, Demissew Amenu et al. 9 citations

Maternal depression is pregnancy and childbirth-related depression during pregnancy (prenatal depression (PND)) or after delivery (postpartum depression (PPD)). It is a recognized global public health concern with extensive repercussions adversely affecting women's well-being and the developmental progress of infants. Mindfulness-based interventions (MBIs) have been shown to be effective in...

DOI: 10.1186/s12884-025-07286-9 (opens in new tab) Full text (opens in new tab) Maternal depression Meta-analysis Mindfulness-based interventions Perinatal depression +4

SLOW BUT STEADY: ORAL KETAMINE AS AN EFFECTIVE ADJUNCT IN DEPRESSION, ANXIETY AND PTSD

The International Journal of Neuropsychopharmacology February 12, 2025 *William Sulis

Abstract Intravenous and intranasal Ketamine have become important options for the rapid relief of symptoms in PTSD, Suicidality and in Treatment Resistant Depression and Anxiety. However, they are costly, require at least an out- patient clinic setting and have relatively short lived benefits. I present a pilot study examining 8 patients treated with oral Ketamine, 5 mg/kg for 12 treatments....

METHOXPHENIDINE, A DESIGNER DRUG OR A POSSIBLE ROUTE FOR RESEARCH TO DEPRESSION TREATMENT?

The International Journal of Neuropsychopharmacology February 12, 2025 *Bronislav Jurásek, Magdaléna Vágnerová, Hana Walaská et al.

Abstract Background Methoxphenidine (MXP) is a new psychoactive substance that belongs to the group of arylethylamines. Even though MXP has a different pharmacophore than ketamine, both of these substances belong to the dissociatives. To date, MXP has been associated with several intoxications and despite it being banned in most countries it is still available over the internet.1 Aims &...

Efficacy and safety of ketamine and esketamine in reducing the incidence of postpartum depression: an updated systematic review and meta-analysis.

BMC Pregnancy and Childbirth February 6, 2025 Moaz Yasser Darwish, Abdallah A Helal, Yousif Ahmed Othman et al. 8 citations

Postpartum depression (PPD) is categorized by the Disorders-Fifth Edition as depression that begins during pregnancy or within the first month after giving birth. Ketamine and esketamine have shown promising results in the treatment of several depressive disorders, which suggests that they may have a role in the prevention of PPD. This systematic review and meta-analysis aim to update evidence...

DOI: 10.1186/s12884-025-07186-y (opens in new tab) Full text (opens in new tab) Esketamine Mental health Postpartum depression ppd Antidepressants +2

Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges

Brain Sciences February 6, 2025 Michael J Lucido, Boadie W Dunlop 15 citations

Background/Objectives: Non-response to initial treatment options for major depressive disorder (MDD) is a common clinical challenge with profound deleterious impacts for affected patients. Few treatments have received regulatory approval for treatment-resistant depression (TRD). Methods: A systematic search of United States and European Union clinical trials registries was conducted to identify...

DOI: 10.3390/brainsci15020161 (opens in new tab) Psilocybin Depression treatment antidepressants Therapy Medication +12

Quantitative evaluation of multiple treatment regimens for treatment-resistant depression.

The International Journal of Neuropsychopharmacology February 4, 2025 Yulin Feng, Yinghua Lv, Juan Yang et al. 3 citations

This study aims to quantitatively evaluate the efficacy and safety of various treatment regimens for treatment-resistant depression (TRD) across oral, intravenous, and intranasal routes to inform clinical guidelines. A systematic review identified randomized controlled trials on TRD, with efficacy measured by changes in the Montgomery-Åsberg Depression Rating Scale (MADRS). We developed...

DOI: 10.1093/ijnp/pyaf007 (opens in new tab) Full text (opens in new tab) Efficacy evaluation Modeling and simulation Treatment-resistant depression trd Refractory depression +5